Aveo Pharmaceuticals Inc

AVEO 
(NASDAQ) 
 
$ 0.7080 <%= Resources.Global.txtDown %>
Updated 24/06/2019
Change % -3.79% Stock price decreasing
Change -0.0279 Stock price decreasing
Volume 925,776
High $ 0.7301
Low $ 0.7010
Open $ 0.7260
ISIN
Prev close $ 0.7359
# of shares 160.74M
Market cap 113.80M USD
Intraday

Market closed
Aveo Pharmaceuticals Inc
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  0.71 -2.1% Stock price decreasing 1.1% Stock price increasing 23.8% Stock price increasing -57.6% Stock price decreasing -68.3% Stock price decreasing
Powered by TradingView

News about Aveo Pharmaceuticals Inc

  • English
  • Regulatory news
26 Apr
 
25 Apr
 
25 Apr
 
23 Apr
 
23 Apr
 
19 Apr
 
18 Apr
 
18 Apr
 
16 Apr
 
16 Apr
 

Company profile

AVEO Pharmaceuticals Inc is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need. The Company aim is to retain North American rights to its oncology portfolio while securing partners in development and commercialization outside of North America. It is seeking to develop and commercialize its lead candidate tivozanib in North America as a treatment for advanced or metastatic renal cell carcinoma (RCC). It has outlicensed tivozanib (FOTIVDA) for oncology in Europe and other territories outside North America. Tivozanib is approved in the European Union as well as Norway and Iceland for the first-line treatment of adult patients with RCC.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
26 June 2019 06:12:20
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB6 - 2019-06-26 07:12:20 - 2019-06-26 06:12:20 - 1000 - Website: OKAY